Consolidated income statement For the year ended 31 December 2017 2017 2016 Exceptional items Exceptional items 2017 and other 2017 2016 and other 2016 Core adjustments Reported Core adjustments Reported results Note 5 results results Note 5 results Note $m $m $m $m $m $m Revenue 4 1,936 1,936 1,950 1,950 Cost of sales 4 963 6 969 932 32 964 Gross profit 4 973 6 967 1,018 32 986 Sales and marketing expenses 188 48 236 184 37 221 General and administrative expenses 238 1 239 208 36 244 Research and development expenses 115 6 121 126 24 150 Other operating expenses net 8 46 1,072 1,118 81 12 69 Total operating expenses 587 1,127 1,714 599 85 684 Operating profit loss 4 386 1,133 747 419 117 302 Finance income 9 2 93 95 3 9 12 Finance expense 10 60 26 86 63 41 104 Profit loss before tax 328 1,066 738 359 149 210 Tax 11 72 29 101 80 28 52 Profit loss for the year 6 256 1,095 839 279 121 158 Attributable to: Non-controlling interests 34 4 4 3 3 Equity holders of the parent 252 1,095 843 276 121 155 256 1,095 839 279 121 158 Earnings loss per share cents Basic 13 105.0 351.3 118.5 66.5 Diluted 13 104.6 349.8 117.9 66.2 122 122 Financial statements Consolidated statement of comprehensive income For the year ended 31 December 2017 2017 2016 Exceptional Items Exceptional Items 2017 and other 2017 2016 and other 2016 Core adjustments Reported Core adjustments Reported Results Note 5 results results Note 5 results Note $m $m $m $m $m $m Profit loss for the year 256 1,095 839 279 121 158 Other Comprehensive Income loss Items that may be reclassified subsequently to the income statement, net of tax: Effect of change in investment designated at fair value 23 2 2 1 1 Exchange difference on translation of foreign operations 20 20 90 90 Total comprehensive income loss for the year 278 1,095 817 190 121 69 Attributable to: Non-controlling interests 34 3 3 Equity holders of the parent 275 1,095 820 190 121 69 278 1,095 817 190 121 69 123 123 Hikma Pharmaceuticals PLC Consolidated balance sheet At 31 December 2017 2017 2016 Note $m $m Non-current assets Goodwill 14 282 682 Other intangible assets 14 503 1,037 Property, plant and equipment 15 828 969 Investment in associates and joint ventures 16 6 7 Deferred tax assets 17 135 172 Financial and other non-current assets 18 60 48 1,814 2,915 Current assets Inventories 19 488 459 Income tax receivable 53 2 Trade and other receivables 20 707 759 Collateralised and restricted cash 21 4 7 Cash and cash equivalents 22 227 155 Other current assets 23 95 66 1,574 1,448 Total assets 3,388 4,363 Current liabilities Bank overdrafts and loans 24 86 117 Trade and other payables 25 365 343 Income tax provision 82 112 Other provisions 26 26 27 Other current liabilities 27 238 319 797 918 Net current assets 777 530 Non-current liabilities Long-term financial debts 28 670 721 Obligations under finance leases 29 20 21 Deferred tax liabilities 17 49 15 Other non-current liabilities 32 324 277 1,063 1,034 Total liabilities 1,860 1,952 Net assets 1,528 2,411 Equity Share capital 33 40 40 Share premium 282 282 Own shares 35 1 1 Other reserves 1,193 2,075 Equity attributable to equity holders of the parent 1,514 2,396 Non-controlling interests 34 14 15 Total equity 1,528 2,411 The financial statements of Hikma Pharmaceuticals PLC, registered number 5557934, on pages 122 to 171 were approved by the Board of Directors on 13 March 2018 and signed on its behalf by: Said Darwazah Mazen Darwazah Director Director 13 March 2018 124 124 Financial statements Consolidated statement of changes in equity For the year ended 31 December 2017 Equity attributable Merger and to equity NonRevaluation Translation Retained Total Share Share Own shareholders controlling Total reserves reserves earnings reserves capital premium shares of the parent interests equity $m $m $m $m $m $m $m $m $m $m Balance at 1 January 2016 38 161 1,144 1,021 35 282 1 1,337 15 1,352 Profit for the year 155 155 155 3 158 Effect of change in investment designated at fair value Note 23 1 1 1 1 Currency translation loss 87 87 87 3 90 Total comprehensive income loss for the year 87 156 69 69 69 Total transactions with owners, recognised directly in equity Issue of equity shares for acquisition of a subsidiary 1,039 1,039 5 1,044 1,044 Cost of equity-settled employee share scheme Note 38 22 22 22 22 Deferred tax arising on share-based payments 1 1 1 1 Dividends on ordinary shares Note 12 77 77 77 1 78 Acquisition of subsidiaries 1 1 Balance at 31 December 2016 and 1 January 2017 1,077 248 1,246 2,075 40 282 1 2,396 15 2,411 Loss for the year 1,039 196 843 843 4 839 Effect of change in investment designated at fair value Note 23 1 1 1 1 Currency translation gain loss 21 21 21 1 20 Total comprehensive loss income for the year 1,039 21 197 821 821 3 818 Total transactions with owners, recognised directly in equity Cost of equity-settled employee share scheme Note 38 22 22 22 22 Dividends on ordinary shares Note 12 79 79 79 2 81 Adjustment arising from change in non-controlling interests 4 4 4 2 6 Balance at 31 December 2017 38 227 1,382 1,193 40 282 1 1,514 14 1,528 During the year the Group acquired the remaining stake in Ibn Al Baytar bringing the total ownership to 100%.
This was completed in April 2017.
A loss of $1,039 million has been allocated from retained earnings to the merger and revaluation reserves in relation to West-Ward Columbus impairment Notes 5, 14 and 15.
125 125 Hikma Pharmaceuticals PLC Consolidated cash flow statement For the year ended 31 December 2017 2017 2016 Note $m $m Cash generated from operating activities 36 546 369 Income tax paid 103 76 Net cash generated from operating activities 443 293 Investing activities Purchases of property, plant and equipment 107 122 Proceeds from disposal of property, plant and equipment 4 1 Purchase of intangible assets 44 68 Proceeds from disposal of intangible assets 24 Cash received from investment in joint ventures 2 Investment in financial and other non-current assets 2 11 Investment in available for sale investments 8 6 Acquisition of business undertakings net of cash acquired 3 515 Finance income 1 2 Net cash used in investing activities 151 695 Financing activities Increase decrease in collateralised and restricted cash 3 4 Proceeds from issue of long-term financial debts 349 471 Repayment of long-term financial debts 401 326 Proceeds from short-term borrowings 323 345 Repayment of short-term borrowings 349 337 Dividends paid 79 77 Dividends paid to non-controlling shareholders of subsidiaries 2 1 Interest paid 57 54 Purchase of non-controlling interest in subsidiary 6 Payment proceeds from co-development and earnout payment agreement, net 1 2 Net cash used in generated by financing activities 220 19 Net increase decrease in cash and cash equivalents 72 383 Cash and cash equivalents at beginning of year 155 553 Foreign exchange translation movements 15 Cash and cash equivalents at end of year 227 155 During the year, the Group received a $3 million payment from Boehringer Ingelheim in respect of the price adjustment receivable to the West-Ward Columbus acquisition.
